Advances in Clinical Treatment of Malignant Melanoma: B-RAF Kinase Inhibition

Czech version

Authors: P. Heneberg
Authors‘ workplace: 3. lékařská fakulta Univerzity Karlovy, Praha
Published in: Klin Onkol 2011; 24(4): 256-264
Category: Reviews

Overview

Malignant melanoma is an aggressive cancer of pigment-producing cells, derivates of the neural crest. Surgical resection is the most effective form of treatment during initial phases of the disease. Advanced stages are usually treated by adjuvant immunotherapy (interferon α) or dacarbazine + multiferon. Response and survival rates are extremely poor. The emerging approach of personalized medicine brings about significant advances in the treatment of melanoma. Apart from administration of imatinib for a small subgroup of melanomas harbouring KIT mutations, the most promising approach is the use of B-RAF kinase inhibitors. The previously tested RAF inhibitors (e. g. sorafenib) did not perform better compared to conventional chemotherapy or immunotherapy. However, the results are much more promising with the recently developed inhibitor PLX4032 (Plexxikon; RG7204, Roche Pharmaceuticals; vemurafenib). This inhibitor targets tumours harbouring B-RAF^V600E of B-RAF^V600K activating mutations, which are present in 40–70% of malignant melanomas. An absence of the above mentioned activating mutations or parallel presence of activating RAS mutations (e. g. RAS^G12D) should be used as contraindications. The use of PLX4032 provides better outcome than any of the currently used therapies, including partial or complete response recorded in 81% of patients, and prolonged median survival. Currently, this drug is being tested in phase II and III trials. The incidence of PLX4032-related adverse effects is relatively high; acquired resistance repeatedly occurring within several months of treatment may also represent a significant problem. Combined therapy is probably needed to further increase the complete response rate and to prolong survival. This should either include some of the currently used chemotherapeutics, or alternatively it may employ inhibitors of some of the kinases capable of stimulating the MEK and ERK kinases independently of B-RAF (e. g. COT). Nevertheless, even PLX4032 monotherapy should be viewed as a significant improvement of the current state-of-the-art treatment of malignant melanoma.

Key words:
RAF1 – thyroid cancer – protein kinase inhibitors – antitumor agents – genetic predisposition to disease – neoplastic process – genetic markers – pharmacological biomarkers

Sources

1. Ferlay J, Shin HR, Bray F, Forman D et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer. France: Lyon 2010. [aktualizováno 9. ledna 2011; citováno 9. ledna 2011]. Available from: http://globocan.iarc.fr.

2. Brychtová S, Fiurášková M, Sedláková E et al. Molekulární změny ovlivňující progresi maligního melanomu. Klin Onkol 2005; 18(4): 145–148.

3. Pavey S, Johansson P, Packer L et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 2004; 23(23): 4060–4067.

4. Solomon DA, Kim JS, Cronin JC et al. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res 2008; 68(24): 10300–10306.

5. Hussussian CJ, Struewing JP, Goldstein AM et al. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8(1): 15–21.

6. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353(20): 2135–2147.

7. Guldberg P, Thor Straten P, Birck A et al. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 1997; 57(17): 3660–3663.

8. Stretch JR, Gatter KC, Ralfkiaer E et al. Expression of mutant p53 in melanoma. Cancer Res 1991; 51(21): 5976–5979.

9. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363(9): 809–819.

10. Bollag G, Hirth P, Tsai J et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467(7315): 596–599.

11. Zásady cytostatické léčby maligních onkologických onemocnění. Česká onkologická společnost ČLS JEP. 11. vydání [aktualizováno 1. srpna 2010; citováno 4. října 2010]. Dostupné z: http://www.linkos.cz/odbornici/info_praxe/standardy.php? t=1.

12. Michálek J, Matějková E, Smejkalová J et al. Využití tumor infiltrujících lymfocytů u pacientů s metastazujícím melanomem. Klin Onkol 2007; 20(4): 298–301.

13. Poprach A, Michalová E, Pavlík T et al. Současný stav testování chemorezistence nádorů ex vivo v Masarykově onkologickém ústavu v Brně. Klin Onkol 2008; 21(3): 116–121.

14. Keiholz U, Goey SH, Punt CJ et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997; 15(7): 2578–2588.

15. Balch CA, Atkins MB, Sober AJ. Cutaneous melanoma. In: DeVita VT Jr, Hellman S, Rosenberg SA et al (eds). Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins Philadelphia 2005.

16. Uldrijan S, Nenutil R, Fait V et al. Melanomové fragmenty a jejich krátkodobá kultivace jako nástroj pro sledování odezvy na cytotoxické látky s rozdílným mechanismem účinku. Klin Onkol 2001; 14(1): 25–30.

17. Emuss V, Garnett M, Mason C et al. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res 2005; 65(21): 9719–9726.

18. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417(6892): 949–954.

19. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004; 6(4): 313–319.

20. Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116(6): 855–867.

21. Ikenoue T, Hikiba Y, Kanai F et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 2003; 63(23): 8132–8137.

22. Hingorani SR, Jacobetz MA, Roberson GP et al. Suppression of BRAF^V599E in human melanoma abrogates transformation. Cancer Res 2003; 63(17): 5198–5202.

23. Wellbrock C, Ogilvie L, Hedley D et al. ^V599EB-RAF is an oncogene in melanocytes. Cancer Res 2004; 64(7): 2338–2342.

24. Sumimoto H, Miyagishi M, Miyoshi H et al. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 2004; 23(36): 6031–6039.

25. Karasarides M, Chiloeches A, Hayward R et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004; 23(37): 6292–6298.

26. Tsai J, Lee JT, Wang W et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008; 105(8): 3041–3046.

27. Søndergaard JN, Nazarian R, Wang Q et al. Differential sensitivity of melanoma cell lines with BRAF^V600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 2010; 8: 39.

28. Hatzivassiliou G, Song K, Yen I et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464(7287): 431–435.

29. Heneberg P. Zpřesněme indikaci podávání inhibitorů kinázové aktivity EGFR. Klin Onkol 2011; 24(2): 87–93.

30. Cichowski K, Jänne PA. Drug discovery: Inhibitors that activate. Nature 2010; 464(7287): 358–359.

31. Heidorn SJ, Milagre C, Whittaker S et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140(2): 209–221.

32. Poulikakos PI, Zhang C, Bollag G et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464(7287): 427–430.

33. Kong HH, Cowen EW, Azad NS et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007; 56(1): 171–172.

34. Schwartz GK, Robertson S, Shen A et al. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. J Clin Oncol 2009; 27: 15. Abstract 3513.

35. Kefford R, Arkenau H, Brown MP et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010; 28. Abstract 8503.

36. Dumaz N, Hayward R, Martin J et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006; 66(19): 9483–9491.

37. Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468(7326): 973–977.

38. Villanueva J, Vultur A, Lee JT et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18(6): 683–695.

39. Heneberg P. Inhibitory, které aktivují. Vesmír 2010; 89: 356.

40. Nunes-Xavier C, Romá-Mateo C, Ríos P et al. Dual-specificity MAP kinase phosphatases as targets of cancer treatment. Anticancer Agents Med Chem 2011; 11(1): 109–132.

41. Jailkhani N, Chaudhri VK, Rao KV. Regulatory cascades of protein phosphatases: implications for cancer treatment. Anticancer Agents Med Chem 2011; 11(1): 64–77.

42. Heneberg P. Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs. Curr Med Chem 2009; 16(6): 706–733.

43. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 2005; 6(11): 827–837.

44. Johannessen CM, Boehm JS, Kim SY et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468(7326): 968–972.

45. Carvajal RD, Chapman PB, Wolchok JD et al. A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J Clin Oncol 2009; 27. Abstract 9001.

46. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64(19): 7099–7109.

47. Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006; 95(5): 581–586.

48. McDermott DF, Sosman JA, Gonzalez R et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008; 26(13): 2178–2185.

49. Hauschild A, Agarwala SS, Trefzer U et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009; 27(17): 2823–2830.

50. Ledford H. Melanoma drug wins US approval. Nature 2011; 471(7340): 561.

51. Yang H, Higgins B, Kolinsky K et al. RG7204 (PLX4032), a selective BRAF^V600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010; 70(13): 5518–5527.

52. Rubinstein JC, Sznol M, Pavlick AC et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010; 8: 67.

53. Michaloglou C, Vredeveld LC, Soengas MS et al. BRAF^E600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436(7051): 720–724.

54. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice, verze 7.0. Masarykova univerzita, Brno 2007. [aktualizováno 14. ledna 2011; citováno 14. ledna 2011]. Dostupné z: http://www.svod.cz.

55. Heneberg P. Supposed steep increase in publications on cruciate ligament and other topics. Eur J Orthop Surg Traumatol 2011; 21(6): 401–405.